echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Lancet Clinical Discovery! One week of radiotherapy is effective for breast cancer patients! It's equivalent to three weeks of radiotherapy!

    Lancet Clinical Discovery! One week of radiotherapy is effective for breast cancer patients! It's equivalent to three weeks of radiotherapy!

    • Last Update: 2020-05-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    May 22, 2020 /
    BioValleyBIOON/-- A study found that for patients with breast cancerearly
    after surgery, a week of radiation treatment at a shorter but larger daily dose is as safe and effective as standard three-week therapyDuring the COVID-19 pandemic, there was an urgent need for hospitals to reduce the need for the NHSstudies have found that patients with early breast cancer can be treated with shorter but larger daily radiotherapy doses than current standards, with a shorter total durationa ground-breaking study involving more than 4,000 patients assessed the effectiveness of two different radiotherapy doses, five times a week, compared with the current standard radiotherapy, which offered 15 treatments in three weeksshortenthed the course of treatment, safe and effective
    researchers found that after-surgery procedures for early breast cancer patients were as safe and effective as the current standard three-week course of treatmentThe findings were published recently in the Lancetimage source: https://cn.bing.com
    Phase III randomizedclinical trial
    funded by the National Institutes of Health (NIHR), the UK's largest health and social care research funding body and led by a team at the Cancer Institute in Londonreduce treatment time and save resources
    the trial, which recruited patients from 97 NHS hospitals in the UK, shows how to save valuable medical resources while reducing patient care time Professor professor from North Midlands Hospital, who the study's clinical lead researcher, said: 'This landmark trial shows that a week-long schedule is expected to become a new international standard for breast cancer patients who need radiotherapy for surgery At a time when patients and healthcare services are facing increasing challenges around the world, this has significant benefits in terms of convenience and cost "
    improve patient experience and improve treatment outcomes
    Professor of Clinical Trials at the Institute of Cancer Research in London, and Statistics at the Clinical Trials and Statistics, and co-senior author of the study, said: "We are always looking for ways to improve and enhance cancer treatment so that we can make treatment more effective and improve the patient's experience If the same results can be achieved within a week, no one will want to come to the hospital for three weeks of radiation treatment we expect these findings to be included in breast cancer treatment guidelines around the world, and we have seen NHS hospitals looking to switch to five-dose treatment plans as they face challenges during the coronavirus pandemic "
    "I feel like one of the lucky ones", Karen Davis, owner of a hair and hair and wig studio in Staffordshire In 2013, the 45-year-old was diagnosed with breast cancer and volunteered for the Fast-forward clinical trial Karen shared her experience with the study: "When I heard that this trial meant I was going to have radiotherapy in a week, not three weeks later, I thought, 'This is great.' 'I was nervous until I started the treatment and I knew I only needed five days of treatment It also means I can get back to work earlier, which means a lot to my own start-up In addition to the regular tamoxifen pills, radiation therapy was the last time I received treatment and my body was checked well, so I felt i was one of the lucky ones It would be great if more early-stage breast cancer patients could now receive shorter radiation therapy -- it would make it easier for patients to lead a normal life during treatment I'm glad I volunteered for this research -- especially if it could help other women Professor Nick Lemoine, medical director of the National Institutes of Health's Clinical Research Network (CRN), the progress, said: "Breast cancer is the most common cancer in women and is the most frequently used patient in the UK for radiotherapy facilities The NIHR is committed to funding practice-changing research, and this landmark study supports this position This study shows that innovation can be both clinical and cost-effective For those planning, providing or receiving NHS and social care, innovation is an important indicator of the wider impact of medical treatment and testing image source: https://cn.bing.com
    reducing the cost of radiation treatment for the NHS
    breast cancer is the most common cancer among women worldwide, and about 30 percent of radiotherapy services in many of the richest countries are used to treat breast cancer in the UK, there are about 55,200 new cases of breast cancer each year - about 150 a day Of the 81% of the confirmed patients, surgical removal of tumours is part of their main cancer treatment, and 63% receive radiation therapy Reducing the standard radiotherapy for breast cancer from three weeks to one week would save the NHS up to 40 million pounds a year has been used to improve treatment through research
    history, women have received 25 daily doses of radiation therapy over a five-week period More than a decade ago, the BRITISH Clinical Trials, led by Professor John Yarnold and co-ordinated by Cancer Research UK, to reduce the standard therapeutic dose to 15 doses per day within three weeks in this new study, researchers hope to further reduce the dose and total time Between 2011 and 2014, researchers recruited 4,096 patients from 97 centres in the UK who underwent breast cancer surgery and randomly assigned them to one of three treatment options one-third of the participants received a standard plan of 15 daily doses over three weeks, with a total total dose of 40 gori (grey, or Gori-radiation dose units) The remaining patients were divided into two groups, each receiving five treatments during a week at a total dose of 26 gori or 27 gori the study collected post-treatment details, including patient and health professional assessments of side effects Five years after radiotherapy, the risk of recurrence of the same breast cancer was very low, similar to the three treatment groups the long-term side effects of the 26-week plan are similar compared to the standard three-week plan proposed new standards of care for most breast cancer patients
    Professor Brunt added: "The benefit for patients is shorter radiotherapy, which is comparable to the effectiveness and side effects of cancer compared to a three-week treatment regimen Therefore, we recommend that this program, five times a week, with a dose of 26 gori, can be considered the new standard of care for most breast cancer patients (biovalleybioon.com) References: One-week course of radiotherapy can benefit women with early stage breast cancer, finds
    Adrian Murray brunt et al.
    Publicfractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-non-lying, randomised, phase 3, the trial Lancet (2020) DOI: 10.1016/S0140-6736 (20) 30932-6
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.